Home Crystal structure of 2-[3,5-bis(trifluoromethyl)benzylsulfanyl]-5-(5-bromothiophen-2-yl)-1,3,4-oxadiazole, C15H7BrF6N2OS2
Article Open Access

Crystal structure of 2-[3,5-bis(trifluoromethyl)benzylsulfanyl]-5-(5-bromothiophen-2-yl)-1,3,4-oxadiazole, C15H7BrF6N2OS2

  • Fatmah A. M. Al-Omary , Fahdah S. Alanazi , Hazem A. Ghabbour and Ali A. El-Emam EMAIL logo
Published/Copyright: November 16, 2016
Download Article (PDF)
Become an author with De Gruyter Brill
Submit Manuscript Author Information
Zeitschrift für Kristallographie - New Crystal Structures
From the journal Zeitschrift für Kristallographie - New Crystal Structures Volume 232 Issue 1

Abstract

C15H7BrF6N2OS2, monoclinic, P21/c (no. 14), a = 18.8292(14) Å, b = 11.4568(9) Å, c = 8.3400(6) Å, β = 90.791(3)°, V = 1799.0(2) Å3, Z = 4, Rgt(F) = 0.068, wRref(F2) = 0.199, T = 296(2).

CCDC no.:: 1481834

The crystal structure is shown in the figure. Tables 1 and 2 contain details on crystal structure and measurement conditions and a list of the atoms including atomic coordinates and displacement parameters.

Table 1

Data collection and handling.

Crystal:Colourless plate
Size:0.57 × 0.35 × 0.07 mm
Wavelength:Mo Kα radiation (0.71073 Å)
μ:25.8 cm−1
Diffractometer, scan mode:Bruker APEX-II, φ and ω
2θmax, completeness:50°, >99%
N(hkl)measured, N(hkl)unique, Rint:21302, 3161, 0.100
Criterion for Iobs, N(hkl)gt:Iobs > 2 σ(Iobs), 1970
N(param)refined:272
Programs:SHELX [23], Bruker programs [24]
Table 2

Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å2).

AtomxyzUiso*/Ueq
Br10.72439(5)0.71399(9)−0.13559(11)0.0903(4)
F1−0.0040(4)0.3361(8)0.6335(10)0.177(4)
F20.0787(4)0.2435(6)0.5630(13)0.190(4)
F30.0346(5)0.3718(7)0.4127(8)0.169(3)
F4a0.0955(12)0.5157(15)1.1082(13)0.120(6)
F5a0.1041(11)0.6846(12)1.0352(14)0.119(6)
F6a0.1969(4)0.5984(13)1.0983(9)0.088(4)
F5Xb0.0676(8)0.588(6)1.056(6)0.148(17)
F6Xb0.137(2)0.6986(9)1.035(5)0.19(4)
F4Xb0.156(5)0.502(4)1.117(3)0.21(4)
S10.57631(10)0.73792(16)0.0189(2)0.0639(5)
S20.33239(10)0.51981(15)0.4713(2)0.0647(5)
O10.4458(2)0.5598(4)0.2987(5)0.0542(11)
N10.4281(3)0.7312(5)0.1833(7)0.0625(15)
N20.3680(3)0.7040(5)0.2801(7)0.0626(15)
C10.6481(4)0.6519(7)−0.0195(8)0.0615(18)
C20.6428(4)0.5444(7)0.0450(9)0.0643(19)
H2A0.67790.48530.03420.077*
C30.5797(4)0.5298(6)0.1297(8)0.0584(17)
H3A0.56730.45980.18360.070*
C40.5381(4)0.6272(5)0.1264(7)0.0506(15)
C50.4706(4)0.6447(5)0.1977(7)0.0499(15)
C60.3828(4)0.6037(5)0.3432(8)0.0528(16)
C70.2608(4)0.6235(5)0.5014(8)0.0573(17)
H7A0.27910.69360.55760.069*
H7B0.24040.64800.39670.069*
C80.2044(3)0.5650(5)0.6009(7)0.0494(15)
C90.1578(4)0.4840(6)0.5370(8)0.0605(18)
H9A0.16190.46210.42760.073*
C100.1052(4)0.4339(6)0.6279(8)0.0589(17)
C110.0978(4)0.4661(6)0.7855(8)0.0589(17)
H11A0.06140.43260.84840.071*
C120.1435(3)0.5474(5)0.8519(7)0.0489(15)
C130.1965(3)0.5955(5)0.7604(7)0.0484(15)
H13A0.22820.65060.80760.058*
C140.0560(6)0.3450(9)0.5561(11)0.088(3)
C150.1348(5)0.5857(7)1.0223(9)0.0676(19)

aOccupancy: 0.74(3); bOccupancy: 0.26(3).

Source of material

3,5-Bis(trifluoromethyl)benzyl bromide (614 mg, 2.0 mmol) and anhydrous potassium carbonate (276 mg, 2.0 mmol) were added to a solution of 5-(5-bromothiophen-2-yl)-1,3,4-oxadiazole-2-thiol (526 mg, 2.0 mmol), in N,N-dimethylformamide (5 mL), and the mixture was stirred for 6 h at room temperature. Water (15 mL) was added to the reaction mixture and stirring was continued for 10 min. The precipitated crude product was filtered, washed with water, dried and crystallized from ethanol to yield 646 mg (66%) of the title compound (C15H7BrF6N2OS2) as shiny transparent plates. M.P.: 373–375 K. Single crystals were obtained by slow evaporation from EtOH/CHCl3 (1:2) at room temperature. 1H NMR (DMSO-d6, 500.13 MHz): δ 4.73 (s, 2H, CH2), 7.43 (d, 1H, thiophene-H, J = 4.0 Hz), 7.60 (d, 1H, thiophene-H, J = 4.0 Hz), 8.03 (s, 1H, Ar—H), 8.24 (s, 2H, Ar—H). 13C NMR (DMSO-d6, 125.76 MHz): δ 35.06 (CH2), 117.87, 121.92, 124.76, 125.75, 130.52, 130.87, 131.51, 132.60, 141.38 (Ar—C, thiophene-C & CF3), 161.04, 163.01 (oxadiazole-C). ESI-MS, m/z: 489.1 (M + H, 100%)+, 491.1 (M + 2 + H, 98%)+.

Experimental details

H atoms were placed in calculated positions and were included in the refinement in the riding model approximation. The fluorine atoms of the disorderd CF3-group were located on a difference Fourier map and refined freely.

Discussion

1,3,4-Oxadiazole derivatives were early identified as a structural motif of particular interest in medicinal chemistry, material sciences and agrochemistry. Some 1,3,4-oxadiazoles have occupied a unique situation in the field of medicinal chemistry as pharmacophores or auxophores possessing diverse pharmacological activities, including antibacterial [1; 2; 3; 4; 5], anticancer [6; 7; 8; 9; 10], antiviral [11; 12; 13], antihypertensive [14, 15], anti-inflammatory [16, 17] and antioxidant [18] activities. In addition, some 1,3,4-oxadiazoles are currently used as safe herbicides for crop protection [19; 20; 21]. Moreover, 1,3,4-oxadiazole derivatives are widely employed electron-transporting and hole-blocking materials in the development of organic light-emitting diodes (OLEDs) [22].

The asymmetric unit cell of the title compound contains one independent molecule. The oxadiazole ring (O1/C5/N1/N2/C6)) makes dihedral angles 7.74° and 81.39° with the bromothiophene moiety (S1/C1—C4) and phenyl moiety (C8—C13), respectively. The trifluromethyl group is disordered over two sets of sites in a 0.736 : 0.379 ratio. The molecules packed in the crystal structure without any intermolecular hydrogen bonds.

Acknowledgements

This research project was supported by a grant from the Research Center of the Female Scientific and Medical Colleges, Deanship of Scientific Research, King Saud University.

References

1 Prakash, O.; Kumar, M.; Kumar, R.; Sharma, C.; Aneja, K. R.: Hypervalent iodine(III) mediated synthesis of novel unsymmetrical 2,5-disubstituted 1,3,4-oxadiazoles as antibacterial and antifungal agents. Eur. J. Med. Chem. 45 (2010) 4252–4257.10.1016/j.ejmech.2010.06.023Search in Google Scholar PubMed

2 Fuloria, N. K.; Singh, V.; Shaharyar, M.; Ali, M.: Synthesis and antimicrobial evaluation of some new oxadiazoles derived from phenylpropionohydrazides. Molecules 14 (2009) 1898–1903.10.3390/molecules14051898Search in Google Scholar PubMed PubMed Central

3 Morgan, R. Y.; Mkadmah, A. M.; Beedham, I.; Elmanama, A. A.; Mattar, M. R.; Raftery, J.; Pritchard, R. G.; Awadallah, A. M.; Grandier, J. M.: Antibacterial activities of novel nicotinic acid hydrazides and their conversion into N-acetyl-1,3,4-oxadiazoles. Bioorg. Med. Chem. Lett. 24 (2014) 5796–5800.10.1016/j.bmcl.2014.10.029Search in Google Scholar PubMed

4 Rane, R. A.; Gutte, S. D.; Sahu, N. U.: Synthesis and evaluation of novel 1,3,4-oxadiazole derivatives of marine bromopyrrole alkaloids as antimicrobial agent. Bioorg. Med. Chem. Lett. 22 (2012) 6429–6432.10.1016/j.bmcl.2012.08.061Search in Google Scholar PubMed

5 Ogata, M.; Atobe, H.; Kushida, H.; Yamamoto, K.: In vitro sensitivity of mycoplasmas isolated from various animals and sewage to antibiotics and nitrofurans. J. Antibiot. 24 (1971) 443–451.10.7164/antibiotics.24.443Search in Google Scholar PubMed

6 Pinna, G. A.; Murineddu, G.; Murruzzu, C.; Zuco, V.; Zunino, F.; Cappelletti, G.; Solano, L.; Villa, S.: Synthesis, modelling, and antimitotic properties of tricyclic systems characterised by a 2-(5-phenyl-1H-pyrrol-3-yl)-1,3,4-oxadiazole moiety. ChemMedChem 4 (2009) 998–1009.10.1002/cmdc.200800428Search in Google Scholar PubMed

7 Gamal El-Din, M. M.; El-Gamal, M. I.; Abdel-Maksoud, M. S.; Yoo, K. H.; Oh, C.-H.: Synthesis and invitro antiproliferative activity of new 1,3,4-oxadiazole derivatives possessing sulfonamide moiety. Eur. J. Med. Chem. 90 (2015) 45–52.10.1016/j.ejmech.2014.11.011Search in Google Scholar PubMed

8 Ouyang, X.; Piatnitski, E. L.; Pattaropong, V.; Chen, X.; He, H. Y.; Kiselyov, A. S.; Velankar, A.; Kawakami, J.; Labelle, M.; Smith, L.; Lohman, J.; Lee, S. P.; Malikzay, A.; Fleming, J.; Gerlak, J.; Wang, Y.; Rosler, R. L.; Zhou, K.; Mitelman, S.; Camara, M.; Surguladze, D.; Doody, J. F.; Tuma, M. C.: Oxadiazole derivatives as a novel class of antimitotic agents: Synthesis, inhibition of tubulin polymerization, and activity in tumor cell lines. Bioorg. Med. Chem. Lett. 16 (2006) 1191–1196.10.1016/j.bmcl.2005.11.094Search in Google Scholar PubMed

9 Zhang, K.; Wang, P.; Xuan, L.-N.; Fu, X.-Y.; Jing, F.; Li, S.; Liu, Y.-M.; Chen, B.-Q.: Synthesis and antitumor activities of novel hybrid molecules containing 1,3,4-oxadiazole and 1,3,4-thiadiazole bearing Schiff base moiety. Bioorg. Med. Chem. Lett. 24 (2014) 5154–5156.10.1016/j.bmcl.2014.09.086Search in Google Scholar PubMed

10 Du, Q.-R.; Li, D.-D.; Pi, Y.-Z.; Li, J.-R.; Sun, J.; Fang, F.; Zhong, W.-Q.; Gong, H.-B.; Zhu, H.-L.: Novel 1,3,4-oxadiazole thioether derivatives targeting thymidylate synthase as dual anticancer/antimicrobial agents. Bioorg. Med. Chem. 21 (2013) 2286–2297.10.1016/j.bmc.2013.02.008Search in Google Scholar PubMed

11 Summa, V.; Petrocchi, A.; Bonelli, F.; Crescenzi, B.; Donghi, M.; Ferrara, M.; Fiore, F.; Gardelli, C.; Paz, O. G.; Hazuda, D. J.; Jones, P.; Kinzel, O.; Laufer, R.; Monteagudo, E.; Muraglia, E.; Nizi, E.; Federica, F.; Pace, P.; Pescatore, G.; Scarpelli, R.; Stillmock, K.; Winter, M. V.; Rowley, M.: Discovery of raltegravir, a potent, selective orally bioavailable HIV-Integrase inhibitor for the treatment of HIV-AIDS infection. J. Med. Chem. 51 (2008) 5843–5855.10.1021/jm800245zSearch in Google Scholar

12 Wu, W.; Chen, Q.; Tai, A.; Jiang, G.; Ouyang, G.: Synthesis and antiviral activity of 2-substituted methylthio-5-(4-amino-2-methylpyrimidin-5-yl)-1,3,4-oxadiazole derivatives. Bioorg. Med. Chem. Lett. 25 (2015) 2243–2246.10.1016/j.bmcl.2015.02.069Search in Google Scholar

13 El-Emam, A. A.; Al-Deeb, O. A.; Al-Omar, M.; Lehmann, J.: Synthesis, antimicrobial, and anti-HIV-1 activity of certain 5-(1-adamantyl)-2-substituted thio-1,3,4-oxadiazoles and 5-(1-adamantyl)-3-substituted aminomethyl-1,3,4-oxadiazoline-2-thiones. Bioorg. Med. Chem. 12 (2004) 5107–5113.10.1016/j.bmc.2004.07.033Search in Google Scholar

14 Vardan, S.; Smulyan, H.; Mookherjee, S.; Eich, R.: Effects of tiodazosin, a new antihypertensive, hemodynamics and clinical variables. Clin. Pharmacol. Ther. 34 (1983) 290–296.10.1038/clpt.1983.170Search in Google Scholar

15 Schlecker, R.; Thieme, P. C.: The synthesis of antihypertensive 3-(1,3,4-oxadiazol-2-yl)phenoxypropanolahines. Tetrahedron 44 (1983) 3289–3294.10.1016/S0040-4020(01)85962-7Search in Google Scholar

16 Bansal, S.; Bala, M.; Suthar, S. K.; Choudhary, S.; Bhattacharya, S.; Bhardwaj, V.; Singla, S.; Joseph, A.: Design and synthesis of novel 2-phenyl-5-(1,3-diphenyl-1H-pyrazol-4-yl)-1,3,4-oxadiazoles as selective COX-2 inhibitors with potent anti-inflammatory activity. Eur. J. Med. Chem. 80 (2014) 167–174.10.1016/j.ejmech.2014.04.045Search in Google Scholar PubMed

17 Kadi, A. A.; El-Brollosy, N. R.; Al-Deeb, O. A.; Habib, E. E.; Ibrahim, T. M.; El-Emam, A. A.: Synthesis, antimicrobial, and anti-inflammatory activities of novel 2-(1-adamantyl)-5-substituted-1,3,4-oxadiazoles and 2-(1-adamantylamino)-5-substituted-1,3,4-thiadiazoles. Eur. J. Med. Chem. 42 (2007) 235–242.10.1016/j.ejmech.2006.10.003Search in Google Scholar PubMed

18 Ma, L.; Xiao, Y.; Li, C.; Xie, Z.-L.; Li, Z.-L. D.-D.; Wang, Y.-T.; Ma, H.-T.; Zhu, H.-L.; Wang, M.-H.; Ye, Y.-H.: Synthesis and antioxidant activity of novel Mannich base of 1,3,4-oxadiazole derivatives possessing 1,4-benzodioxan. Bioorg. Med. Chem. 21 (2013) 6763–6770.10.1016/j.bmc.2013.08.002Search in Google Scholar PubMed

19 Shi, W.; Qian, X.; Zhang, R.; Song, G.: Synthesis and quantitative structure-activity relationships of new 2,5-disubstituted-1,3,4-oxadiazoles. J. Agri. Food Chem. 49 (2001) 124–130.10.1021/jf0007941Search in Google Scholar PubMed

20 Murakami, Y.; Nishimune, T.; Sueki, K.: Studies on pesticides for a rice plant accumulation of oxadiazon and its metabolites in processed foods. Toxicol. Environ. Chem. 45 (1994) 225–235.10.1080/02772249409358088Search in Google Scholar

21 Milinkevich, K. A.; Yoo, C. L.; Sparks, T. C.; Lorsbach, B. A.; Kurth, M. J.: Synthesis and biological activity of 2-(3,4-dihydroisoxazol-5-yl)-1,3,4-oxadiazoles. Bioorg. Med. Chem. Lett. 19 (2009) 5796–5798.10.1016/j.bmcl.2009.07.139Search in Google Scholar PubMed

22 Zhang, Y.; Zuniga, C.; Kim, S.-J.; Cai, D.; Barlow, S.; Salman, S.; Coropceanu, V.; Brédas, J. L.; Kippelen, B.; Marder, S.: Polymers with carbazole-oxadiazole side chains as ambipolar hosts for phosphorescent light-emitting diodes. Chem. Mater. 23 (2011) 4002–4015.10.1021/cm201562pSearch in Google Scholar

23 Sheldrick, G. M.: A short history of SHELX. Acta Crystallogr. A64 (2008) 112–122.10.1107/S0108767307043930Search in Google Scholar PubMed

24 Brucker. APEX2, SAINT and SADABS. Brucker AXS Inc., Madison, Wisconsin, USA, (2009).Search in Google Scholar

Received: 2016-6-12
Accepted: 2016-10-28
Published Online: 2016-11-16
Published in Print: 2017-1-1

©2016 Fatmah A. M. Al-Omary et al., published by De Gruyter.

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Articles in the same Issue

  1. Cover and Frontmatter
  2. Editorial
  3. Twenty years of crystal structure publication and the road ahead
  4. Crystal Structures
  5. Crystal structure of poly-[triaqua-(μ4-5′-carboxy-[1,1′-biphenyl]-2,3,3′-tricarboxylate-κ6O1,O2:O3,O4:O5:O6)praseodymium(III), C16H13O11Pr
  6. Crystal structure of (R)-1-(2,3-dihydro-1H-pyrrolizin-5-yl)-2,3-dihydroxypropan-1-one, C10H13NO3
  7. Crystal structure of (E)-4-nitro-2-((2-phenoxyphenylimino)methyl)phenol, C19H14N2O4
  8. Crystal structure of 3,3′-di(furan-2-yl)-5,5′-bi-1,2,4-triazine
  9. Crystal structure of 11-(p-coumaroyloxy)-tremetone, C22H20O5
  10. The crystal structure of 1,3-bis(2,6-diiso-propylphenyl)imidazol-2-ylidene)-dibromido-(1-methyl-1H-imidazole-κ1N)palladium(II) – ethyl acetate – water (1/1/1), C31H42Br2N4Pd
  11. Crystal structure of 2-((3-(5-methyl-1-phenyl-1H-1,2,3-triazol-4-yl)-1-phenyl-1H-pyrazol-4-yl)methylene)-1H-indene-1,3(2H)-dione, C28H19N5O2
  12. Crystal structure of 2-(5-(4-fluorophenyl)-3-p-tolyl-4,5-dihydro-1H-pyrazol-1-yl)-4-(5-methyl-1-p-tolyl-1H-1,2,3-triazol-4-yl)thiazole, C29H25FN6S
  13. Crystal structure of poly-[aqua-(μ7-benzene-1,3,5-tricarboxylato)-(μ3-1,2,4-triazol-1-ido)dicobalt(II)], C11H7Co2N3O7
  14. Crystal constructure of 16(S)-methyl-6α-carboxy-1, 15-dioxo-6, 7-seco-ent-kaur-2-en-7, 20-olide, C20H24O6
  15. Crystal structure of 1-(benzo[d]thiazol-2-yl)-3-phenylthiourea, C14H11N3S2
  16. Crystal structure of 3-(2-bromophenyl)-1,1-dimethylthiourea, C9H11BrN2S
  17. Crystal structure of 1-(adamantan-1-yl)-3-(3-chlorophenyl)thiourea, C17H21ClN2S
  18. Crystal structure of 3-(adamantan-1-yl)-1-(4-bromophenyl)urea, C17H21BrN2O
  19. Crystal structure of (Z)-Ethyl 2-cyano-2-(3-phenylthiazolidin-2-ylidene) acetate, C14H14N2O2S
  20. Crystal structure of methyl 2b-ethyl-1a,2a,2b,2b1,3,5,10,11-octahydro-1H-oxireno[2′,3′:6,7]indolizino[8,1-cd]carbazole-4-carboxylate, C21H24N2O3
  21. Crystal structure of 2-amino-5-oxo-4-(3,4,5-trimethoxy-phenyl)-4,5,6,7-tetrahydro-cyclopenta[b]pyran-3-carbonitrile, C18H18N2O5
  22. Crystal structure of 1,2,3-trimethyl-2,3-dihydro-1H-perimidine, C14H16N2
  23. Crystal structure of bis(2,6-dihydroxymethyl)pyridine-κ3N,O,O′)-bis(μ2-6-chloropyridin-2-olato-κ3N,O:O)-bis(6-chloropyridin-2-olato-κO)-bis(nitrato-κ2O,O′)digadolinium(III), C34H30Cl4Gd2N8O14
  24. Crystal structure of 8-isopropyl-8-aza-bicyclo[3.2.1]octan-3-yl 3-hydroxy-2-phenylpropanoate, C19H27NO3
  25. Crystal structure of 1-methyl-3-[((naphthalen-2-ylsulfonyl)oxy)imino]indolin-2-one, C19H14N2O4S
  26. Crystal structure (7,8-bis(diisopropylphosphino)-7,8-dicarba-nido-undecaborane-κ2P,P′)-(benzoato-κ2O,O′)nickel(II), C21H42B9NiO2P2
  27. Crystal structure of methyl-2-methyl-4-(2-oxo-2-phenylethyl)-5-phenyl-1H-pyrrole-3-carboxylate, C21H19NO3
  28. Crystal structure of 2-[(2-oxo-thiazolidine-3-carbonyl)sulfamoyl]-methy-benzoic acid methyl ester, C13H14N2O6S2
  29. Crystal structure of N′-(2-phenylacetyl)thiophene-2-carbohydrazide monohydrate, C13H14N2O3S
  30. Crystal structure of 1,1′-(hexane-1,6-diyl)bis(3-methyl-1H-imidazol-3-ium) bis(hexafluoro phosphate), C14H24F12N4P2
  31. Crystal structure of di-μ-chlorido-bis[1,2-bis(dicyclohexylphosphino)-1,2-dicarba-closo-dodecaborane-κ2P,P′]zinc(II), C52H108B20Cl2P4Zn2
  32. Crystal structure of dibromido-bis[μ-1-[(2-methyl-1H-benzoimidazol-1-yl)methyl]-1H-benzotriazole-κN]mercury(II), C30H26Br2HgN10
  33. Crystal structure of bis(μ-nitrato-κ2O:O)-bis[1,2-bis(diphenylphosphino)-1,2-dicarba-closo-dodecaborane-κ2P,P′]disilver(I) dicloromethane monosolvate, C54H64B20Cl4O6P4Ag2
  34. Crystal structure of dinuclear dichloridobis(dimethylformamide-kO)bis[μ2-3-(2-oxyphenyl)-5-(pyrazin-2-yl)-1,2,4-triazol-1ido-κ4-O,N:N′,N′′(2−)]diiron(III) − dimethylformamide (1/1), C36H42Cl2Fe2N14O6
  35. Crystal structure of diaqua-dinitrato-κO-bis(4-(1H-pyrazol-3-yl)pyridine-κN)manganese(II), C16H18MnN8O8
  36. Crystal structure of (Z)-6-methoxy-2-(2,2,2-trifluoro-1-hydroxyethylidene)-2,3-dihydro-1H-inden-1-one, C12H6F6O3
  37. Crystal Structure of 4-(2-chloroacetamido)pyridinium chloride monohydrate, C7H10Cl2N2O2
  38. Crystal structure of 2-amino-4-(4-chloro-phenyl)-5-oxo-5,6,7,8-tetrahydro-4H-chromene-3-carbonitrile, C16H13ClN2O2
  39. Crystal structure of (E)-1-(2-(thiophen-2-ylmethylene)hydrazinyl)phthalazine hydrochloride–ethanol (1/1), C15H17ClN4OS
  40. Crystal structure of N,N-diethyl-5-bromo-3,4-dihydro-2,4-dioxopyrimidine-1(2H)-carboxamide, C9H12BrN3O3
  41. Crystal structure of 3-(2-(4-chlorophenyl)-3-hydroxy-3,3-diphenylpropyl)-1,1-dimethylurea, C24H25ClN2O2
  42. Crystal structure of 3-(4-chlorophenyl)-1,1-dimethylthiourea, C9H11ClN2S
  43. Crystal structure of 2-amino-4-(4-bromo-phenyl)-7-methyl-5-oxo-4H,5H-pyrano[4,3-b]pyran-3-carbonitrile, C16H11BrN2O3
  44. Crystal structure of 4-(3,4-dimethyl-phenyl)-2-methyl-5-oxo-1,4,5,6,7,8-hexahydro-quinoline-3-carboxylic acid ethyl ester, C21H25NO3
  45. Crystal structure of (E)-2-({4-hydroxy-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]phenyl} methylidene)-1-indanone, C23H26N2O3
  46. Crystal structure of tripropylammonium 2′-carboxy-[1,1′-biphenyl]-2-carboxylate – [1,1′-biphenyl]-2,2′-dicarboxylic acid (2/1), C60H72N2O12
  47. Crystal structure of catena-poly-{aqua-[μ2-1,2-bis((1H-imidazol-1-yl)methyl)benzene-κ2N:N′]-[μ2-4,4′-(dimethylsilanediyl)dibenzato-κ3O,O′:O′]nickel(II)}, C30H30N4NiO5Si
  48. The crystal structure of 1-(4-bromophenyl)-2-(4-(4-fluorophenyl)piperazin-1-yl)ethanol, C18H20BrFN2O1
  49. Crystal structure of trimethylammonium 4-((4-carboxyphenyl)sulfonyl)benzoate, C17H19NO6S
  50. Crystal structure of syn-2,4-di-o-tolylpentane-2,4-diol, C19H24O2
  51. Crystal structure of 2-[3,5-bis(trifluoromethyl)benzylsulfanyl]-5-(5-bromothiophen-2-yl)-1,3,4-oxadiazole, C15H7BrF6N2OS2
  52. Crystal structure of (E)-3-((naphthalen-1-ylimino)methyl)-4-nitrophenol, C17H12N2O3
  53. Crystal structure of 2-dichloromethyl-2-p-nitrophenyl-1,3-dioxolane, C10H9Cl2NO4
  54. Crystal structure of (1,4,8,11-tetraazacyclotetradecane)palladium(II) tetracyanopalladate(II), C14H24N8Pd2
  55. Crystal structure of 2-(4-oxo-2-thioxothiazolidin-3-yl)acetic acid monohydrate, C5H7NO4S2
  56. Crystal structure of a P4-bridged (η5-pentamethyl-cyclopentadienyl)(η5-adamantylcyclopentadienyl) titanium(III)complex, C50H66P4Ti2
  57. Crystal structure of cis-bis(2,2′-bipyrimidine-κ2N,N′)bis(thiocyanato-κN)nickel(II), C18H12N10NiS2
  58. Crystal structure of cis-bis(2,2′-bipyridine-κ2N,N′)dibromidomanganese(II), C20H16Br2MnN4
  59. Crystal structure of cis-bis(2,2′-bipyridine-κ2N,N′)bis(thiocyanato-κN)nickel(II), C22H16N6NiS2
  60. Crystal structure of trans-dibromido(1,4,8,11-tetraazacyclotetradecane)nickel(II), C10H24Br2N4Ni
  61. Crystal structure of cis-tetrabromidobis(pyridine-κN)platinum(IV), C10H10Br4N2Pt
  62. Crystal structure of (E)-5-((4-chlorophenyl)diazenyl)-2-(5-(4-fluorophenyl)-3-(thiophen-2-yl)-4,5-dihydro-1H-pyrazol-1-yl)-4-methylthiazole, C23H17ClFN5S2
  63. The crystal structure of 3-((1R,2S)-1-methylpyrrolidin-1-ium-2-yl)pyridin-1-ium tetrachloridocobaltate(II) monohydrate, C10H18Cl4CoN2O
https://doi.org/10.1515/ncrs-2016-0188
Creative Commons
BY-NC-ND 3.0

Articles in the same Issue

  1. Cover and Frontmatter
  2. Editorial
  3. Twenty years of crystal structure publication and the road ahead
  4. Crystal Structures
  5. Crystal structure of poly-[triaqua-(μ4-5′-carboxy-[1,1′-biphenyl]-2,3,3′-tricarboxylate-κ6O1,O2:O3,O4:O5:O6)praseodymium(III), C16H13O11Pr
  6. Crystal structure of (R)-1-(2,3-dihydro-1H-pyrrolizin-5-yl)-2,3-dihydroxypropan-1-one, C10H13NO3
  7. Crystal structure of (E)-4-nitro-2-((2-phenoxyphenylimino)methyl)phenol, C19H14N2O4
  8. Crystal structure of 3,3′-di(furan-2-yl)-5,5′-bi-1,2,4-triazine
  9. Crystal structure of 11-(p-coumaroyloxy)-tremetone, C22H20O5
  10. The crystal structure of 1,3-bis(2,6-diiso-propylphenyl)imidazol-2-ylidene)-dibromido-(1-methyl-1H-imidazole-κ1N)palladium(II) – ethyl acetate – water (1/1/1), C31H42Br2N4Pd
  11. Crystal structure of 2-((3-(5-methyl-1-phenyl-1H-1,2,3-triazol-4-yl)-1-phenyl-1H-pyrazol-4-yl)methylene)-1H-indene-1,3(2H)-dione, C28H19N5O2
  12. Crystal structure of 2-(5-(4-fluorophenyl)-3-p-tolyl-4,5-dihydro-1H-pyrazol-1-yl)-4-(5-methyl-1-p-tolyl-1H-1,2,3-triazol-4-yl)thiazole, C29H25FN6S
  13. Crystal structure of poly-[aqua-(μ7-benzene-1,3,5-tricarboxylato)-(μ3-1,2,4-triazol-1-ido)dicobalt(II)], C11H7Co2N3O7
  14. Crystal constructure of 16(S)-methyl-6α-carboxy-1, 15-dioxo-6, 7-seco-ent-kaur-2-en-7, 20-olide, C20H24O6
  15. Crystal structure of 1-(benzo[d]thiazol-2-yl)-3-phenylthiourea, C14H11N3S2
  16. Crystal structure of 3-(2-bromophenyl)-1,1-dimethylthiourea, C9H11BrN2S
  17. Crystal structure of 1-(adamantan-1-yl)-3-(3-chlorophenyl)thiourea, C17H21ClN2S
  18. Crystal structure of 3-(adamantan-1-yl)-1-(4-bromophenyl)urea, C17H21BrN2O
  19. Crystal structure of (Z)-Ethyl 2-cyano-2-(3-phenylthiazolidin-2-ylidene) acetate, C14H14N2O2S
  20. Crystal structure of methyl 2b-ethyl-1a,2a,2b,2b1,3,5,10,11-octahydro-1H-oxireno[2′,3′:6,7]indolizino[8,1-cd]carbazole-4-carboxylate, C21H24N2O3
  21. Crystal structure of 2-amino-5-oxo-4-(3,4,5-trimethoxy-phenyl)-4,5,6,7-tetrahydro-cyclopenta[b]pyran-3-carbonitrile, C18H18N2O5
  22. Crystal structure of 1,2,3-trimethyl-2,3-dihydro-1H-perimidine, C14H16N2
  23. Crystal structure of bis(2,6-dihydroxymethyl)pyridine-κ3N,O,O′)-bis(μ2-6-chloropyridin-2-olato-κ3N,O:O)-bis(6-chloropyridin-2-olato-κO)-bis(nitrato-κ2O,O′)digadolinium(III), C34H30Cl4Gd2N8O14
  24. Crystal structure of 8-isopropyl-8-aza-bicyclo[3.2.1]octan-3-yl 3-hydroxy-2-phenylpropanoate, C19H27NO3
  25. Crystal structure of 1-methyl-3-[((naphthalen-2-ylsulfonyl)oxy)imino]indolin-2-one, C19H14N2O4S
  26. Crystal structure (7,8-bis(diisopropylphosphino)-7,8-dicarba-nido-undecaborane-κ2P,P′)-(benzoato-κ2O,O′)nickel(II), C21H42B9NiO2P2
  27. Crystal structure of methyl-2-methyl-4-(2-oxo-2-phenylethyl)-5-phenyl-1H-pyrrole-3-carboxylate, C21H19NO3
  28. Crystal structure of 2-[(2-oxo-thiazolidine-3-carbonyl)sulfamoyl]-methy-benzoic acid methyl ester, C13H14N2O6S2
  29. Crystal structure of N′-(2-phenylacetyl)thiophene-2-carbohydrazide monohydrate, C13H14N2O3S
  30. Crystal structure of 1,1′-(hexane-1,6-diyl)bis(3-methyl-1H-imidazol-3-ium) bis(hexafluoro phosphate), C14H24F12N4P2
  31. Crystal structure of di-μ-chlorido-bis[1,2-bis(dicyclohexylphosphino)-1,2-dicarba-closo-dodecaborane-κ2P,P′]zinc(II), C52H108B20Cl2P4Zn2
  32. Crystal structure of dibromido-bis[μ-1-[(2-methyl-1H-benzoimidazol-1-yl)methyl]-1H-benzotriazole-κN]mercury(II), C30H26Br2HgN10
  33. Crystal structure of bis(μ-nitrato-κ2O:O)-bis[1,2-bis(diphenylphosphino)-1,2-dicarba-closo-dodecaborane-κ2P,P′]disilver(I) dicloromethane monosolvate, C54H64B20Cl4O6P4Ag2
  34. Crystal structure of dinuclear dichloridobis(dimethylformamide-kO)bis[μ2-3-(2-oxyphenyl)-5-(pyrazin-2-yl)-1,2,4-triazol-1ido-κ4-O,N:N′,N′′(2−)]diiron(III) − dimethylformamide (1/1), C36H42Cl2Fe2N14O6
  35. Crystal structure of diaqua-dinitrato-κO-bis(4-(1H-pyrazol-3-yl)pyridine-κN)manganese(II), C16H18MnN8O8
  36. Crystal structure of (Z)-6-methoxy-2-(2,2,2-trifluoro-1-hydroxyethylidene)-2,3-dihydro-1H-inden-1-one, C12H6F6O3
  37. Crystal Structure of 4-(2-chloroacetamido)pyridinium chloride monohydrate, C7H10Cl2N2O2
  38. Crystal structure of 2-amino-4-(4-chloro-phenyl)-5-oxo-5,6,7,8-tetrahydro-4H-chromene-3-carbonitrile, C16H13ClN2O2
  39. Crystal structure of (E)-1-(2-(thiophen-2-ylmethylene)hydrazinyl)phthalazine hydrochloride–ethanol (1/1), C15H17ClN4OS
  40. Crystal structure of N,N-diethyl-5-bromo-3,4-dihydro-2,4-dioxopyrimidine-1(2H)-carboxamide, C9H12BrN3O3
  41. Crystal structure of 3-(2-(4-chlorophenyl)-3-hydroxy-3,3-diphenylpropyl)-1,1-dimethylurea, C24H25ClN2O2
  42. Crystal structure of 3-(4-chlorophenyl)-1,1-dimethylthiourea, C9H11ClN2S
  43. Crystal structure of 2-amino-4-(4-bromo-phenyl)-7-methyl-5-oxo-4H,5H-pyrano[4,3-b]pyran-3-carbonitrile, C16H11BrN2O3
  44. Crystal structure of 4-(3,4-dimethyl-phenyl)-2-methyl-5-oxo-1,4,5,6,7,8-hexahydro-quinoline-3-carboxylic acid ethyl ester, C21H25NO3
  45. Crystal structure of (E)-2-({4-hydroxy-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]phenyl} methylidene)-1-indanone, C23H26N2O3
  46. Crystal structure of tripropylammonium 2′-carboxy-[1,1′-biphenyl]-2-carboxylate – [1,1′-biphenyl]-2,2′-dicarboxylic acid (2/1), C60H72N2O12
  47. Crystal structure of catena-poly-{aqua-[μ2-1,2-bis((1H-imidazol-1-yl)methyl)benzene-κ2N:N′]-[μ2-4,4′-(dimethylsilanediyl)dibenzato-κ3O,O′:O′]nickel(II)}, C30H30N4NiO5Si
  48. The crystal structure of 1-(4-bromophenyl)-2-(4-(4-fluorophenyl)piperazin-1-yl)ethanol, C18H20BrFN2O1
  49. Crystal structure of trimethylammonium 4-((4-carboxyphenyl)sulfonyl)benzoate, C17H19NO6S
  50. Crystal structure of syn-2,4-di-o-tolylpentane-2,4-diol, C19H24O2
  51. Crystal structure of 2-[3,5-bis(trifluoromethyl)benzylsulfanyl]-5-(5-bromothiophen-2-yl)-1,3,4-oxadiazole, C15H7BrF6N2OS2
  52. Crystal structure of (E)-3-((naphthalen-1-ylimino)methyl)-4-nitrophenol, C17H12N2O3
  53. Crystal structure of 2-dichloromethyl-2-p-nitrophenyl-1,3-dioxolane, C10H9Cl2NO4
  54. Crystal structure of (1,4,8,11-tetraazacyclotetradecane)palladium(II) tetracyanopalladate(II), C14H24N8Pd2
  55. Crystal structure of 2-(4-oxo-2-thioxothiazolidin-3-yl)acetic acid monohydrate, C5H7NO4S2
  56. Crystal structure of a P4-bridged (η5-pentamethyl-cyclopentadienyl)(η5-adamantylcyclopentadienyl) titanium(III)complex, C50H66P4Ti2
  57. Crystal structure of cis-bis(2,2′-bipyrimidine-κ2N,N′)bis(thiocyanato-κN)nickel(II), C18H12N10NiS2
  58. Crystal structure of cis-bis(2,2′-bipyridine-κ2N,N′)dibromidomanganese(II), C20H16Br2MnN4
  59. Crystal structure of cis-bis(2,2′-bipyridine-κ2N,N′)bis(thiocyanato-κN)nickel(II), C22H16N6NiS2
  60. Crystal structure of trans-dibromido(1,4,8,11-tetraazacyclotetradecane)nickel(II), C10H24Br2N4Ni
  61. Crystal structure of cis-tetrabromidobis(pyridine-κN)platinum(IV), C10H10Br4N2Pt
  62. Crystal structure of (E)-5-((4-chlorophenyl)diazenyl)-2-(5-(4-fluorophenyl)-3-(thiophen-2-yl)-4,5-dihydro-1H-pyrazol-1-yl)-4-methylthiazole, C23H17ClFN5S2
  63. The crystal structure of 3-((1R,2S)-1-methylpyrrolidin-1-ium-2-yl)pyridin-1-ium tetrachloridocobaltate(II) monohydrate, C10H18Cl4CoN2O
Sign up now to receive a 20% welcome discount
Institutional Access
How does access work?
Have an idea on how to improve our website?
Please write us.
© 2025 De Gruyter Brill
Downloaded on 5.10.2025 from https://www.degruyterbrill.com/document/doi/10.1515/ncrs-2016-0188/html
Scroll to top button